According to Saidian Technology's announcement, revenue for the first three quarters of 2026 is estimated to be 410 million yuan to 430 million yuan, up 36% to 42% year on year; net profit to mother of 158 million yuan to 168 million yuan, up 70% to 80% year on year; deducted non-net profit of 154 million yuan to 164 million yuan, up 81% to 93% year on year. According to the company, early reserve projects have entered the post-clinical stage and commercialization stage one after another, driving the release of customer procurement demand; the cost rate declined further over the same period last year.

According to Saidian Technology's announcement, revenue for the first three quarters of 2026 is estimated to be 410 million yuan to 430 million yuan, up 36% to 42% year on year; net profit to mother of 158 million yuan to 168 million yuan, up 70% to 80% year on year; deducted non-net profit of 154 million yuan to 164 million yuan, up 81% to 93% year on year. According to the company, early reserve projects have entered the post-clinical stage and commercialization stage one after another, driving the release of customer procurement demand; the cost rate declined further over the same period last year.